Vol 50 No 12

"We once again note that even success in the efforts to avoid any payment decreases will be a failure in the long run as overhead continues to rise against flat reimbursement," write Jonathan Rubenstein, MD, and Mark Painter.

"Instant and electronic access by patients to the electronic health record upends some long-established physician-centric traditions of medical practice and documentation and raises some concerns," writes Robert A. Dowling, MD.

Plaintiff’s attorneys are substituting regulations for standard of care.

"What was surprising to me is that the incidence [of kidney cancer] has leveled off over the past 2 years," says Laura Bukavina, MD, MPH.

"Giving to charity can be a very powerful tax-savings tool. Check if you have any appreciated investment assets you could donate instead of cash," writes Jeff Witz, CFP.

“These data clearly show that the efficacy benefit observed at the primary analysis was robust and maintained with longer follow-up, once again supporting lenvatinib and pembrolizumab as a standard of care in first-line advanced RCC,” said Camillo G. Porta, MD.

The addition of pembrolizumab has the potential to improve upon standard care with abiraterone acetate plus prednisone in men with metastatic castration-resistant prostate cancer.

In this interview, Justin Dubin, MD, discusses the development of treatments for male infertility.